Third-party funding

Department of Pharmacology and Toxicology

2025

• Edit-DMD – Genom-Editierung bei Duchenne-Musekeldystrophie (01_BIH_TP2404A). Coordinator: W.H. Zimmermann

2024

• Automated production and analysis of bioartificial organ systems to replace animal testing (AutoOrgan_3R - LW23AT008). Network Coordinator: W.H. Zimmermann
• Deutsche Forschungsgemeinschaft (DFG VO 1568/6-1): “Altered cytosolic calcium buffering contributes to arrhythmogenesis in patients with atrial fibrillation”, (2024-2027), N. Voigt
• BMBF-Projektförderung Alternativmethoden zum Tierversuch "AutoOrgan_3R: Automatisierte Herstellung und Analyse von bioartifiziellen Organsystemen zum Ersatz von Tierversuchen", T. Meyer

2022

• DFG RTG 2824 RP5 “Molecular basis of proteotoxic dysfunctions in models of Alzheimer´s disease and dilated cardiomyopathy” (PIs: A. Ebert/W. Zimmermann)

2021

• DZHK “Alliance for the Identification and Validation of Tagets in Heart Failure” (2021-2025), W. Zimmermann
• DZHK “Allianz für die Regeneration bei Herzinsuffizienz”, MD2 (2021-2025), W. Zimmermann
• Fondation Leducq “Editing the Failing Heart” (2021-2025), W. Zimmermann
• BMBF “Organersatz aus dem Labor“ – Individualisierte Herzmuskulatur für die Behandlung bei Herzinsuffizienz (IndiHEART), W. Zimmermann
• Deutsches Zentrum für Herz-Kreislauf-Forschung e.V. (DZHK), DZHK-BHF-DHF Cooperation: “ “DNA damage in cytoskeletal protein mutation-induced Atrial Fibrillation: a guide to novel treatment and screening targets (DnAFiX)“ , Partnership Research Grant with Prof. Dr. Bianca J.J.M. Brundel, Amsterdam UMC, VUmc., (2021-2024), N. Voigt
• High-throughput Image Analysis by deep learning –IT Infrastructure and Data Integrity, T. Meyer
   

2020

• DFG –SFB 1002 “Fibroblast-Cardiomyocyte Cross-Talk in Health and Disease: Focus on Cardiofibroblastopathies”; Projekt C04 (2020-2025), W. Zimmermann
• DFG-SFB 1002 “In Vivo and In Vitro Disease Models, Projekt S01 (2020-2025), W. Zimmermann
• LabTwin "Advanced Tools for data acquisition in restricted laboratory environments", T. Meyer
   

2019

• DFG MBExC “Stem Cells and Organoids” (2019-2025), W. Zimmermann
• DZHK – BioVAT-HF Early Clinical Trial “Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart-Failure” (2019-2024), W. Zimmermann
   

2018

• Deutsche Forschungsgemeinschaft (DFG), Collaborative Research Center 1002 Project A13 (CRC1002 A13): “Abnormal cytosolic calcium buffering and its role in atrial arrhythmogenesis in patients with heart failure”, (2018-2024), N. Voigt
• Sartorius "Development of automated Pipetting Techniques for Engineered Tissue production", T. Meyer
• DZHK Säule B "Robot-assisted 3D extrusion bioprinting of engineered human myocardium with defined force pattern", T. Meyer

2017

• DFG IRTG 1816 “Phosphorylierungs- und redoxabhängige Signalmechanismen” (2017-2021), W. Zimmermann
   

2016

• “Physics-to-Medicine Initiative” of the Göttingen Campus, Lower Saxony Ministry for Science and Culture (MWK), W. Zimmermann
• Deutsche Forschungsgemeinschaft (DFG VO 1568/3-2): “The role of atrial mitochondrial calcium handling in arrhythmogenesis in patients with atrial fibrillation", (2016-2027), N. Voigt
• Deutsche Forschungsgemeinschaft, International Research Training Group Project 12 (DFG IRTG1816 RP12): “Remodeling of human atrial cardiomyocytes in response to in-vitro tachypacing", (2016-2022), N. Voigt
• Else Kröner-Fresenius-Stiftung (EKFS 2016_A20): “Cellular basis for triggers and perpetuators of postoperative atrial fibrillation.”, (2016-2020), N. Voigt
• DZHK Säule B "Inotropy and Chronotropy Screens in EHM by Optical Analysis in Real Time", T. Meyer
   

2015

• DFG SFB 937 (Collective behavior of soft and biological matter), A18 “Soft matter guided self-assembly of oscillating heart cells into functional macro-myocardium”, W. Zimmermann
   

2014

• Leducq Transatlantic Network of Excellence “Programming the Heart to a Regenerative State”, W. Zimmermann
• NC3Rs – UK National Centre for the Replacement, Refinement and Reduction of Animals in Research; Phase 1 funding for CRACK IT Challenge 13: InPulse, W. Zimmermann
   

2013

• DFG IRTG 1816 RP12 “Redox control of fibroblast-derived extracellular matrix and its implications for cardiomyocyte maturation and homeostasis”, W. Zimmermann
• CIRM/BMBF Early Translation III (FKZ: 13GW0007) “Heart Repair with Human Tissue Engineered Myocardium”, W. Zimmermann
   

2012

• NIH-Progenitor Cell Biology Consortium (PCBC), W. Zimmermann
• DFG SFB 1002 (Modulatory Units in Heart Failure), C04 “Control of the Myocardial Stroma by Fibroblasts” and S “Service project”, W. Zimmermann
   

2011

• DZHK (German Center for Cardiovascular Research), Göttingen Partner Site GOE 3.2 HF “Regeneration from Heart Failure” – FKZ: 81Z3300132, GOE I.1 SCI “Experimental Stem Cell Bank” – FKZ: 81Z7300171, GOE I.2 SCI “Therapeutic Stem Cell Bank” – FKZ: 81Z7300172, W. Zimmermann